Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abatacept for severe anti–tumor necrosis factor α refractory juvenile idiopathic arthritis–related uveitis

Open access
Zulian, Francesco, Balzarin, Marta, Falcini, Fernanda, Martini, Giorgia, Alessio, Maria, Cimaz, Rolando, Cimino, Luca, Zannin, Maria Elisabetta · 2010 · Arthritis Care & Research

Abstract

Objective: To evaluate the safety and efficacy of abatacept in patients with severe juvenile idiopathic arthritis (JIA)–related uveitis refractory or intolerant to immunosuppressive and anti–tumor necrosis factor α (anti‐TNFα) agents. Methods: Patients with JIA‐related uveitis refractory to immunosuppressive and anti‐TNFα agents were treated with intravenous abatacept (10 mg/kg monthly). Side effects, frequency of uveitis flares, and ocular complications before and after treatment were reported. Results: Seven patients (6 females and 1 male) with a mean uveitis duration of 11.6 years entered the study. All patients had failed previous immunosuppressive therapy and ≥2 anti‐TNFα treatments. All patients responded to abatacept and 6 maintained a clinical remission after a mean of 9.2 months of treatment. One patient withdrew from the study with oral mycosis and arthritis flare; no other patients had side effects. The mean frequency of uveitis flares during the 6 months before and after treatment decreased from 3.7 to 0.7 episodes. No new ocular complications or worsening of preexisting ones were reported. Conclusion: Abatacept treatment led to sustained improvement in severe anti‐TNFα–resistant JIA‐related uveitis and was well tolerated in all but 1 patient. These results provide new insights into a possible indication of abatacept for the treatment of uveitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.20115

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Mycophenolate mofetil in the treatment of uveitis in children

    Doycheva, D., Deuter, C., Stuebiger, N., Biester, S., & Zierhut, M. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.094698 · Cited by 106 · cited 5×

    “These agents had been administered at standard dosages for several months, as follows: MTX 10–20 mg/m2 (maximum 25 mg/week); CSA 2–5 mg/kg/day (maximum 200 mg/day); MMF 0.5–1 gm/ m2/day (maximum 2 gm/day); LEF 100 mg for 3 days, and 20 mg daily thereafter; etanercept 0.4 mg/kg twice weekly (maximum 50 mg/week); inflix…”
    BackgroundInfluential

Show all 1 references

Cited by

Metadata

Authors
Zulian, F., Balzarin, M., Falcini, F., Martini, G., Alessio, M., Cimaz, R., Cimino, L., & Zannin, M. E.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2010-05-28
Volume
62
Issue
6
Pages
821-825
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W1975837824
Cited by
179
References
1
FWCI
14.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.